JP2024508672A5 - - Google Patents

Info

Publication number
JP2024508672A5
JP2024508672A5 JP2023547592A JP2023547592A JP2024508672A5 JP 2024508672 A5 JP2024508672 A5 JP 2024508672A5 JP 2023547592 A JP2023547592 A JP 2023547592A JP 2023547592 A JP2023547592 A JP 2023547592A JP 2024508672 A5 JP2024508672 A5 JP 2024508672A5
Authority
JP
Japan
Prior art keywords
variable region
chain variable
seq
nos
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547592A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015711 external-priority patent/WO2022170280A2/en
Publication of JP2024508672A publication Critical patent/JP2024508672A/ja
Publication of JP2024508672A5 publication Critical patent/JP2024508672A5/ja
Pending legal-status Critical Current

Links

JP2023547592A 2021-02-08 2022-02-08 新規抗ｃｄ２４抗体 Pending JP2024508672A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/076075 2021-02-08
CN2021076075 2021-02-08
CN202210088172 2022-01-25
CN202210088172.3 2022-01-25
PCT/US2022/015711 WO2022170280A2 (en) 2021-02-08 2022-02-08 Novel anti-cd24 antibodies

Publications (2)

Publication Number Publication Date
JP2024508672A JP2024508672A (ja) 2024-02-28
JP2024508672A5 true JP2024508672A5 (enExample) 2025-02-18

Family

ID=82741874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547592A Pending JP2024508672A (ja) 2021-02-08 2022-02-08 新規抗ｃｄ２４抗体

Country Status (11)

Country Link
US (1) US20240052052A1 (enExample)
EP (1) EP4288099A4 (enExample)
JP (1) JP2024508672A (enExample)
KR (1) KR20230143177A (enExample)
CN (1) CN117412770A (enExample)
AU (1) AU2022217072A1 (enExample)
CA (1) CA3210934A1 (enExample)
CO (1) CO2023011463A2 (enExample)
IL (1) IL304898A (enExample)
MX (1) MX2023009238A (enExample)
WO (1) WO2022170280A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121311506A (zh) * 2023-06-09 2026-01-09 天境生物科技(上海)有限公司 抗-cd24抗体及其用途
GB202316777D0 (en) 2023-11-01 2023-12-13 Cambridge Entpr Ltd New therapeutic use
TW202535944A (zh) * 2023-11-08 2025-09-16 美商飛斯特醫療公司 Ｃｄ２４抗體
WO2025128830A1 (en) * 2023-12-12 2025-06-19 The Methodist Hospital Therapeutic lilrb regulation for treating neurological disorders
AU2024402617A1 (en) * 2023-12-19 2026-05-14 Pentixapharm Ag Antibodies against cd24
WO2025159754A1 (en) * 2024-01-25 2025-07-31 China Medical University Therapeutic cd24 humanized monoclonal antibodies and anti-tumor translational use
WO2025218729A1 (en) * 2024-04-17 2025-10-23 TJ Biopharma (Shanghai) Co., Ltd. Multifunctional molecules targeting cd24
CN119161485B (zh) * 2024-10-29 2026-03-24 上海中医药大学附属曙光医院 靶向GFRα3的抗体及其制备方法和在抗癌中的应用
WO2026117619A1 (en) * 2024-11-26 2026-06-04 Pheast Therapeutics, Inc. Cd24-binding antibodies
WO2026130747A1 (en) * 2024-12-19 2026-06-25 Pentixapharm Ag Antibodies against cd24

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080002341A (ko) * 2006-06-30 2008-01-04 재단법인서울대학교산학협력재단 Ｃｄ２４를 표적으로 하는 암 억제방법
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies
US11046763B2 (en) * 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
JP6476170B2 (ja) * 2014-04-28 2019-03-06 医化学創薬株式会社 抗ｍｕｃ１抗体又はその抗原結合性断片及びその用途
WO2015200522A2 (en) * 2014-06-25 2015-12-30 Integrated Biotherapeutics, Inc. Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
SG11202010589YA (en) * 2018-05-14 2020-11-27 Oncoimmune Inc Anti-cd24 compositions and uses thereof
WO2020198353A1 (en) * 2019-03-26 2020-10-01 Forty Seven, Inc. Multispecific agents for treatment of cancer
JP2022538870A (ja) * 2019-06-25 2022-09-06 イチロフ テック リミテッド 抗ｃｄ２４抗体及びその使用

Similar Documents

Publication Publication Date Title
JP2022545660A5 (enExample)
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法
JP2025078629A5 (enExample)
JP2024023228A5 (enExample)
RU2019126655A (ru) Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль
JP2022514693A5 (enExample)
IL271325B1 (en) Guidance and navigation control proteins and method of making and using thereof
AU2022217072A1 (en) Novel anti-cd24 antibodies
JP2020529839A5 (enExample)
JP2023159379A (ja) Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途
JP2022542559A5 (enExample)
CN115066274A (zh) 三价结合分子
CA3079363A1 (en) Multispecific antigen binding proteins
JP2024532482A5 (enExample)
JP2025508317A5 (enExample)
JP2024516098A5 (enExample)
JP2024541476A5 (enExample)
JP2024546923A5 (enExample)
IL304295B1 (en) A bispecific antibody with a heterodimeric form with a natural antibody structure ANTI-PD-L1/ANTI-4-1BB and its preparation
JP2024504162A5 (enExample)
JP2022536370A5 (enExample)
JP7641292B2 (ja) 抗ｃｄ１９抗体、その使用方法及び製造方法
TW202321311A (zh) 與scFv等之連接子結合的抗體
RU2022107092A (ru) Новые анти-cldn18.2 антитела
CN117794955A (zh) 与scFv等的接头结合的抗体